You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGadobenic acid
Accession NumberDB00743  (APRD00989)
TypeSmall Molecule
GroupsApproved
DescriptionGadobenic acid (in the form of gadobenate dimeglumine) is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for visualizing the CNS and heart. In contrast to conventional extracellular fluid contrast agents, gadobenate dimeglumine is characterized by a weak and transient binding capacity to serum proteins. This binding leads to an increased relaxivity of gadobenate dimeglumine and, consequently, to a considerably increased signal intensity over that of other agents.
Structure
Thumb
Synonyms
Acide gadobenique
Acido gadobenico
Acidum gadobenicum
Gadobenate
Gadobenic acid
Gadobensäure
External Identifiers
  • B 19036
  • B 19036/7
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Multihanceinjection, solution529 mg/mLintravenousBRACCO DIAGNOSTICS INC2004-11-23Not applicableUs
Multihanceinjection, solution529 mg/mLintravenousBRACCO DIAGNOSTICS INC2004-11-23Not applicableUs
Multihancesolution529 mgintravenousBracco Imaging Canada2004-10-28Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Multihance MultipackBracco
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Gadobenate dimeglumine
127000-20-8
Thumb
  • InChI Key: OCDAWJYGVOLXGZ-VPVMAENOSA-K
  • Monoisotopic Mass: 1058.317829604
  • Average Mass: 1058.15
DBSALT001794
Categories
UNII15G12L5X8K
CAS number113662-23-0
WeightAverage: 667.73
Monoisotopic: 668.09649
Chemical FormulaC22H28GdN3O11
InChI KeyMXZROTBGJUUXID-UHFFFAOYSA-K
InChI
InChI=1S/C22H31N3O11.Gd/c26-18(27)10-23(6-7-24(11-19(28)29)12-20(30)31)8-9-25(13-21(32)33)17(22(34)35)15-36-14-16-4-2-1-3-5-16;/h1-5,17H,6-15H2,(H,26,27)(H,28,29)(H,30,31)(H,32,33)(H,34,35);/q;+3/p-3
IUPAC Name
gadolinium(3+) ion 4-carboxy-8,11-bis(carboxylatomethyl)-5-(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oate
SMILES
[Gd+3].OC(=O)CN(CCN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O)C(COCC1=CC=CC=C1)C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pentacarboxylic acids and derivatives. These are carboxylic acids containing exactly five carboxyl groups.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassPentacarboxylic acids and derivatives
Direct ParentPentacarboxylic acids and derivatives
Alternative Parents
Substituents
  • Pentacarboxylic acid or derivatives
  • Alpha-amino acid
  • Alpha-amino acid or derivatives
  • Benzylether
  • Monocyclic benzene moiety
  • Benzenoid
  • Amino acid or derivatives
  • Carboxylic acid salt
  • Tertiary aliphatic amine
  • Tertiary amine
  • Amino acid
  • Carboxylic acid
  • Dialkyl ether
  • Ether
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organooxygen compound
  • Organic zwitterion
  • Carbonyl group
  • Organic oxide
  • Organic nitrogen compound
  • Organic oxygen compound
  • Amine
  • Organic salt
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationGadobenate Dimeglumine is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for MRI of the heart, as well as and central nervous system in adults to visualize lesions with abnormal brain vascularity or abnormalities in the blood brain barrier, the brain, spine, or other associated tissues.
PharmacodynamicsGadobenate dimeglumine shares the pharmacokinetic properties of the ECF contrast agent gadopentetate dimeglumine; however, gadobenate differs in that is also selectively taken-up by hepatocytes and excreted via the bile (up to 5% of dose). The elimination half-life of gadobenate dimeglumine is approximately 1 hour. It is not metabolized.
Mechanism of actionBased on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed, its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record 2 different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and the T2 (spin-spin or transverse relaxation time). In magnetic resonance imaging (MRI), visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in the T2. When placed in a magnetic field, Gadobenate Dimeglumine shortens both the T1 and the T2 relaxation times in tissues where it accumulates. At clinical doses, Gadobenate Dimeglumine primarily affects the T1 relaxation time, thus producing an increase in signal intensity. Gadobenate Dimeglumine does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars).
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingPlasma protein binding is low, weak, and transient.
Metabolism

Not metabolized.

Route of eliminationGadobenate ion is eliminated predominately via the kidneys, with 78% to 96% of an administered dose recovered in the urine.
Half life1 hour
Clearance
  • 0.093 +/- 0.010 L/hr/kg [healthy male subjects receiving 3 single-dose IV administration with doses from 0.005-0.4 mmol/kg]
ToxicityGadolinium-based radiocontrast agents like gadobenate dimeglumine are cytotoxic to renal cells. The toxic effects include apoptosis, cellular energy failure, disruption of calcium homeostasis, and disturbance of tubular cell polarity, and are thought to be linked to oxidative stress.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9749
Blood Brain Barrier-0.9391
Caco-2 permeable-0.691
P-glycoprotein substrateSubstrate0.8261
P-glycoprotein inhibitor INon-inhibitor0.7702
P-glycoprotein inhibitor IINon-inhibitor0.7288
Renal organic cation transporterNon-inhibitor0.8635
CYP450 2C9 substrateNon-substrate0.8598
CYP450 2D6 substrateNon-substrate0.8006
CYP450 3A4 substrateNon-substrate0.6356
CYP450 1A2 substrateNon-inhibitor0.8637
CYP450 2C9 inhibitorNon-inhibitor0.8597
CYP450 2D6 inhibitorNon-inhibitor0.8675
CYP450 2C19 inhibitorNon-inhibitor0.8851
CYP450 3A4 inhibitorNon-inhibitor0.9349
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9905
Ames testNon AMES toxic0.8062
CarcinogenicityNon-carcinogens0.9179
BiodegradationNot ready biodegradable0.8088
Rat acute toxicity2.3557 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8499
hERG inhibition (predictor II)Non-inhibitor0.6371
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Bracco diagnostics inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintravenous529 mg/mL
Solutionintravenous529 mg
Prices
Unit descriptionCostUnit
Multihance 529 mg/ml vial6.87USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4916246 No1995-04-102012-04-10Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.768 mg/mLALOGPS
logP0.92ALOGPS
logP-4.1ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)0.085ChemAxon
pKa (Strongest Basic)9.58ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area213.94 Å2ChemAxon
Rotatable Bond Count20ChemAxon
Refractivity154.36 m3·mol-1ChemAxon
Polarizability48.32 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Pier Lucio Anelli, Pierfrancesco Morisini, Silvia Ceragioli, Fulvio Uggeri, Luciano Lattuada, Roberta Fretta, Aurelia Ferrigato, “Process for the Preparation of Gadobenate Dimeglumine Complex in a Solid Form.” U.S. Patent US20120232151, issued September 13, 2012.

US20120232151
General References
  1. de Haen C, Cabrini M, Akhnana L, Ratti D, Calabi L, Gozzini L: Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S161-8. [PubMed:10608412 ]
  2. Morana G, Salviato E, Guarise A: Contrast agents for hepatic MRI. Cancer Imaging. 2007 Oct 1;7 Spec No A:S24-7. [PubMed:17921081 ]
  3. Vogl TJ, Pegios W, McMahon C, Balzer J, Waitzinger J, Pirovano G, Lissner J: Gadobenate dimeglumine--a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers. AJR Am J Roentgenol. 1992 Apr;158(4):887-92. [PubMed:1546612 ]
  4. Kirchin MA, Pirovano GP, Spinazzi A: Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol. 1998 Nov;33(11):798-809. [PubMed:9818314 ]
  5. Clement O, Siauve N, Cuenod CA, Vuillemin-Bodaghi V, Leconte I, Frija G: Mechanisms of action of liver contrast agents: impact for clinical use. J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S45-52. [PubMed:10608397 ]
  6. Sweetman, Sean C. (2009). Contrast Media. In Martindale : The Complete Drug Reference, 36th Edition 2 Volume Set (36th ed., pp. 1478). Pharmaceutical Press. [ISBN:978-0-85369-840-1 ]
External Links
ATC CodesV08CA08
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (247 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Gadobenic acid.
AmantadineAmantadine may increase the QTc-prolonging activities of Gadobenic acid.
AmiodaroneGadobenic acid may increase the QTc-prolonging activities of Amiodarone.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Gadobenic acid.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Gadobenic acid.
AnagrelideGadobenic acid may increase the QTc-prolonging activities of Anagrelide.
ApomorphineApomorphine may increase the QTc-prolonging activities of Gadobenic acid.
ArformoterolArformoterol may increase the QTc-prolonging activities of Gadobenic acid.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Gadobenic acid.
Arsenic trioxideGadobenic acid may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherGadobenic acid may increase the QTc-prolonging activities of Artemether.
AsenapineGadobenic acid may increase the QTc-prolonging activities of Asenapine.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Gadobenic acid.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Gadobenic acid.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Gadobenic acid.
BedaquilineGadobenic acid may increase the QTc-prolonging activities of Bedaquiline.
BortezomibBortezomib may increase the QTc-prolonging activities of Gadobenic acid.
BuserelinBuserelin may increase the QTc-prolonging activities of Gadobenic acid.
CeritinibGadobenic acid may increase the QTc-prolonging activities of Ceritinib.
ChloroquineChloroquine may increase the QTc-prolonging activities of Gadobenic acid.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Gadobenic acid.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Gadobenic acid.
CisaprideGadobenic acid may increase the QTc-prolonging activities of Cisapride.
CitalopramGadobenic acid may increase the QTc-prolonging activities of Citalopram.
ClarithromycinGadobenic acid may increase the QTc-prolonging activities of Clarithromycin.
ClomipramineClomipramine may increase the QTc-prolonging activities of Gadobenic acid.
ClozapineClozapine may increase the QTc-prolonging activities of Gadobenic acid.
CrizotinibGadobenic acid may increase the QTc-prolonging activities of Crizotinib.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Gadobenic acid.
DasatinibDasatinib may increase the QTc-prolonging activities of Gadobenic acid.
DegarelixDegarelix may increase the QTc-prolonging activities of Gadobenic acid.
DesfluraneDesflurane may increase the QTc-prolonging activities of Gadobenic acid.
DesipramineDesipramine may increase the QTc-prolonging activities of Gadobenic acid.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Gadobenic acid.
DisopyramideGadobenic acid may increase the QTc-prolonging activities of Disopyramide.
DofetilideGadobenic acid may increase the QTc-prolonging activities of Dofetilide.
DolasetronGadobenic acid may increase the QTc-prolonging activities of Dolasetron.
DomperidoneGadobenic acid may increase the QTc-prolonging activities of Domperidone.
DoxepinDoxepin may increase the QTc-prolonging activities of Gadobenic acid.
DronedaroneGadobenic acid may increase the QTc-prolonging activities of Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Gadobenic acid.
EliglustatGadobenic acid may increase the QTc-prolonging activities of Eliglustat.
EribulinEribulin may increase the QTc-prolonging activities of Gadobenic acid.
ErythromycinErythromycin may increase the QTc-prolonging activities of Gadobenic acid.
EscitalopramGadobenic acid may increase the QTc-prolonging activities of Escitalopram.
EzogabineEzogabine may increase the QTc-prolonging activities of Gadobenic acid.
FamotidineFamotidine may increase the QTc-prolonging activities of Gadobenic acid.
FelbamateFelbamate may increase the QTc-prolonging activities of Gadobenic acid.
FingolimodFingolimod may increase the QTc-prolonging activities of Gadobenic acid.
FlecainideGadobenic acid may increase the QTc-prolonging activities of Flecainide.
FluconazoleFluconazole may increase the QTc-prolonging activities of Gadobenic acid.
FluoxetineGadobenic acid may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolGadobenic acid may increase the QTc-prolonging activities of Flupentixol.
FormoterolFormoterol may increase the QTc-prolonging activities of Gadobenic acid.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineGalantamine may increase the QTc-prolonging activities of Gadobenic acid.
GemifloxacinGadobenic acid may increase the QTc-prolonging activities of Gemifloxacin.
GoserelinGoserelin may increase the QTc-prolonging activities of Gadobenic acid.
GranisetronGadobenic acid may increase the QTc-prolonging activities of Granisetron.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Gadobenic acid.
HistrelinHistrelin may increase the QTc-prolonging activities of Gadobenic acid.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Gadobenic acid.
IbandronateIbandronate may increase the QTc-prolonging activities of Gadobenic acid.
IbutilideGadobenic acid may increase the QTc-prolonging activities of Ibutilide.
IloperidoneGadobenic acid may increase the QTc-prolonging activities of Iloperidone.
ImipramineImipramine may increase the QTc-prolonging activities of Gadobenic acid.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Gadobenic acid.
IndapamideIndapamide may increase the QTc-prolonging activities of Gadobenic acid.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Gadobenic acid.
IsradipineIsradipine may increase the QTc-prolonging activities of Gadobenic acid.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Gadobenic acid.
IvabradineIvabradine may increase the QTc-prolonging activities of Gadobenic acid.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Gadobenic acid.
LapatinibLapatinib may increase the QTc-prolonging activities of Gadobenic acid.
LenvatinibGadobenic acid may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Gadobenic acid.
LevofloxacinGadobenic acid may increase the QTc-prolonging activities of Levofloxacin.
LithiumLithium may increase the QTc-prolonging activities of Gadobenic acid.
LopinavirGadobenic acid may increase the QTc-prolonging activities of Lopinavir.
LumefantrineGadobenic acid may increase the QTc-prolonging activities of Lumefantrine.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Gadobenic acid.
MefloquineMefloquine may increase the QTc-prolonging activities of Gadobenic acid.
MethadoneMethadone may increase the QTc-prolonging activities of Gadobenic acid.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Gadobenic acid.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Gadobenic acid.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Gadobenic acid.
MifepristoneMifepristone may increase the QTc-prolonging activities of Gadobenic acid.
MirabegronMirabegron may increase the QTc-prolonging activities of Gadobenic acid.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Gadobenic acid.
MoexiprilMoexipril may increase the QTc-prolonging activities of Gadobenic acid.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Gadobenic acid.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Gadobenic acid.
NicardipineNicardipine may increase the QTc-prolonging activities of Gadobenic acid.
NilotinibGadobenic acid may increase the QTc-prolonging activities of Nilotinib.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Gadobenic acid.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Gadobenic acid.
OctreotideOctreotide may increase the QTc-prolonging activities of Gadobenic acid.
OfloxacinGadobenic acid may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Gadobenic acid.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Gadobenic acid.
OndansetronGadobenic acid may increase the QTc-prolonging activities of Ondansetron.
OxytocinOxytocin may increase the QTc-prolonging activities of Gadobenic acid.
PaliperidoneGadobenic acid may increase the QTc-prolonging activities of Paliperidone.
PanobinostatGadobenic acid may increase the QTc-prolonging activities of Panobinostat.
ParoxetineParoxetine may increase the QTc-prolonging activities of Gadobenic acid.
PasireotidePasireotide may increase the QTc-prolonging activities of Gadobenic acid.
PazopanibGadobenic acid may increase the QTc-prolonging activities of Pazopanib.
PentamidinePentamidine may increase the QTc-prolonging activities of Gadobenic acid.
PerflutrenPerflutren may increase the QTc-prolonging activities of Gadobenic acid.
PimozideGadobenic acid may increase the QTc-prolonging activities of Pimozide.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Gadobenic acid.
PrimaquineGadobenic acid may increase the QTc-prolonging activities of Primaquine.
ProcainamideGadobenic acid may increase the QTc-prolonging activities of Procainamide.
PromazinePromazine may increase the QTc-prolonging activities of Gadobenic acid.
PromethazinePromethazine may increase the QTc-prolonging activities of Gadobenic acid.
PropafenoneGadobenic acid may increase the QTc-prolonging activities of Propafenone.
PropofolPropofol may increase the QTc-prolonging activities of Gadobenic acid.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Gadobenic acid.
QuetiapineGadobenic acid may increase the QTc-prolonging activities of Quetiapine.
QuinidineGadobenic acid may increase the QTc-prolonging activities of Quinidine.
QuinineGadobenic acid may increase the QTc-prolonging activities of Quinine.
RanolazineRanolazine may increase the QTc-prolonging activities of Gadobenic acid.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Gadobenic acid.
RisperidoneRisperidone may increase the QTc-prolonging activities of Gadobenic acid.
RitonavirRitonavir may increase the QTc-prolonging activities of Gadobenic acid.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Gadobenic acid.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Gadobenic acid.
SaquinavirGadobenic acid may increase the QTc-prolonging activities of Saquinavir.
SertralineSertraline may increase the QTc-prolonging activities of Gadobenic acid.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Gadobenic acid.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Gadobenic acid.
SorafenibSorafenib may increase the QTc-prolonging activities of Gadobenic acid.
SotalolGadobenic acid may increase the QTc-prolonging activities of Sotalol.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Gadobenic acid.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Gadobenic acid.
SunitinibSunitinib may increase the QTc-prolonging activities of Gadobenic acid.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Gadobenic acid.
TelavancinGadobenic acid may increase the QTc-prolonging activities of Telavancin.
TelithromycinGadobenic acid may increase the QTc-prolonging activities of Telithromycin.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Gadobenic acid.
TetrabenazineGadobenic acid may increase the QTc-prolonging activities of Tetrabenazine.
ThioridazineGadobenic acid may increase the QTc-prolonging activities of Thioridazine.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Gadobenic acid.
TizanidineTizanidine may increase the QTc-prolonging activities of Gadobenic acid.
TolterodineTolterodine may increase the QTc-prolonging activities of Gadobenic acid.
ToremifeneGadobenic acid may increase the QTc-prolonging activities of Toremifene.
TrazodoneTrazodone may increase the QTc-prolonging activities of Gadobenic acid.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Gadobenic acid.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Gadobenic acid.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Gadobenic acid.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Gadobenic acid.
VandetanibGadobenic acid may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Gadobenic acid.
VemurafenibGadobenic acid may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Gadobenic acid.
VilanterolVilanterol may increase the QTc-prolonging activities of Gadobenic acid.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Gadobenic acid.
VorinostatVorinostat may increase the QTc-prolonging activities of Gadobenic acid.
ZiprasidoneGadobenic acid may increase the QTc-prolonging activities of Ziprasidone.
ZuclopenthixolGadobenic acid may increase the QTc-prolonging activities of Zuclopenthixol.
Food InteractionsNot Available

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Port M, Corot C, Violas X, Robert P, Raynal I, Gagneur G: How to compare the efficiency of albumin-bound and nonalbumin-bound contrast agents in vivo: the concept of dynamic relaxivity. Invest Radiol. 2005 Sep;40(9):565-73. [PubMed:16118549 ]
  2. Wendland MF, Saeed M, Lauerma K, Derugin N, Mintorovitch J, Cavagna FM, Higgins CB: Alterations in T1 of normal and reperfused infarcted myocardium after Gd-BOPTA versus GD-DTPA on inversion recovery EPI. Magn Reson Med. 1997 Mar;37(3):448-56. [PubMed:9055236 ]
  3. Cavagna FM, Maggioni F, Castelli PM, Dapra M, Imperatori LG, Lorusso V, Jenkins BG: Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol. 1997 Dec;32(12):780-96. [PubMed:9406019 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23